retatrutide information UK 2026: Phase 3 Results Retatrutide

These results translated to significant proportions of participants achieving clinically meaningful weight loss: 5% or More Weight Reduction: 92% (4 mg), 100% (8 mg), 100% (12 mg), and 27% (placebo) 10% or More Weight Reduction: 75% (4 mg), 91% (8 mg), 93% (12 mg), and 9% (placebo) 15% or More Weight Reduction: 60% (4 mg), 75% (8 mg), 83% (12 mg), and 2% (placebo) These data underscore retatrutides potential to deliver unprecedented weight loss in a significant portion of individuals with obesity

These tools not only guide treatment decisions but also monitor progress effectively: Recommended Blood Tests and Diagnostics: Comprehensive Metabolic Panel: Evaluate electrolyte balance, kidney function, and liver enzymes

That means your 5 units could deliver less than 0.25 mg of active medication even though you measured perfectly, all because the peptide broke down in storage

Weeks 4 Through 12: The Momentum Phase Dose escalation continues through this period, moving from the starting 2mg toward the 4mg and eventually 6mg range depending on individual protocol structure

Organized by the player-level story, the picture looks like this

In Eli Lilly's Phase 2 clinical trial (published in the New England Journal of Medicine, 2023), 338 adults with obesity or overweight (without diabetes) were treated with retatrutide for 48 weeks